APG Asset Management US Inc. Takes $201,000 Position in Royalty Pharma plc (NASDAQ:RPRX)

APG Asset Management US Inc. bought a new stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 7,872 shares of the biopharmaceutical company's stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Keene & Associates Inc. increased its holdings in shares of Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after purchasing an additional 370 shares in the last quarter. National Bank of Canada FI increased its position in shares of Royalty Pharma by 21.8% in the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 371 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 376 shares during the last quarter. Sanctuary Advisors LLC raised its stake in shares of Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock worth $1,068,000 after buying an additional 388 shares during the last quarter. Finally, Arizona State Retirement System boosted its position in shares of Royalty Pharma by 0.5% in the 4th quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock worth $2,822,000 after buying an additional 537 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on RPRX shares. Citigroup restated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $42.50.

Royalty Pharma Stock Performance

Shares of RPRX stock traded down $0.04 on Tuesday, hitting $32.25. 1,009,746 shares of the stock traded hands, compared to its average volume of 3,233,432. The company has a market capitalization of $18.59 billion, a PE ratio of 22.24, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The company's fifty day moving average is $32.52 and its 200 day moving average is $29.17. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.